Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Adventrx progressing with phase IIb CoFactor trial
CoFactor is Adventrx’s biomodulator designed to enhance the effects and reduce associated toxicity of the widely used cancer drug, 5-fluorouracil (5-FU). The company began dosing patients in the
CoFactor is Adventrx’s biomodulator designed to enhance the effects and reduce associated toxicity of the widely used cancer drug, 5-fluorouracil (5-FU). The company began dosing patients in the
A second collaboration agreement between TorreyPines and Eisai was signed in February of this year to support the discovery of small molecules that lower A-beta42, a peptide involved
The award is from the German Federal Ministry for Education and Research (BMBF) as part of the BioChancePLUS program which helps small and medium-sized biotech companies to develop
After successful completion of enrollment into the first STRAUSS trial (Study of Resistant Staphylococcus Aureus Skin and Skin Structure Infections), focusing on Gram-positive infections, the partnership now plans
The agreement provides Sanofi Pasteur with exclusive access to a portfolio of Agensys’ proprietary colorectal and prostate cancer targets, together with an option to obtain exclusive worldwide licenses
The main objective of this study is to assess the safety and tolerability of cintredekin besudotox administered via convection enhanced delivery (CED) followed by radiation therapy (RT) with
The optimized butyrylcholinesterase protein may have applications in biodefense as a bioscavenger protein for detoxifying nerve agents, and as a treatment for patients with cocaine or heroin drug
Three fractions of v38 AMF-1 were tested against H5N1, the virus responsible for causing avian influenza (bird flu), and all showed excellent potency and selectivity at inhibiting H5N1
Marketing of M-Vax started after recently receiving authorization from the Swiss Health authorities. The vaccine will be produced by Avax’s wholly owned subsidiary, Genopoietic, located in Lyon, France.
The data from preclinical studies in a rat collagen-induced arthritis model of chronic autoimmune inflammatory joint disease demonstrated that daily oral administration of 2-methoxyestradiol (2ME2) resulted in a